These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33999110)

  • 1. Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug Initiative.
    Gunter SJ; Kesselheim AS; Rome BN
    JAMA Intern Med; 2021 Aug; 181(8):1124-1126. PubMed ID: 33999110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.
    Sinha MS; Curfman GD; Carrier MA
    JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104
    [No Abstract]   [Full Text] [Related]  

  • 3. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angst about exclusivity: The potential cost of incentivizing makers of generic drugs.
    Chakradhar S; Khamsi R
    Nat Med; 2017 Oct; 23(10):1114-1116. PubMed ID: 28985215
    [No Abstract]   [Full Text] [Related]  

  • 5. Using a drug-safety tool to prevent competition.
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
    [No Abstract]   [Full Text] [Related]  

  • 6. A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.
    Feldman R; Wang C
    N Engl J Med; 2017 Apr; 376(16):1499-1501. PubMed ID: 28248550
    [No Abstract]   [Full Text] [Related]  

  • 7. Generic Drugs in the United States: Policies to Address Pricing and Competition.
    Gupta R; Shah ND; Ross JS
    Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018.
    Rome BN; Lee CC; Kesselheim AS
    Clin Pharmacol Ther; 2021 Feb; 109(2):367-371. PubMed ID: 32654122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 11. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
    Sarpatwari A; Avorn J; Kesselheim AS
    JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
    [No Abstract]   [Full Text] [Related]  

  • 12. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 13. Determinants of Market Exclusivity for Prescription Drugs in the United States.
    Kesselheim AS; Sinha MS; Avorn J
    JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expensive Medicine: Drug prices are increasingly hard to swallow. Effective remedies prove elusive.
    Bell H
    Minn Med; 2017 May; 100(3):10-17. PubMed ID: 30452131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in time of market exclusivity among top-selling prescription drugs in the United States.
    Wang B; Liu J; Kesselheim AS
    JAMA Intern Med; 2015 Apr; 175(4):635-7. PubMed ID: 25664700
    [No Abstract]   [Full Text] [Related]  

  • 16. The Impact of Off-Patent Drug Acquisitions on Prices.
    Gupta R; Henkel A; Forman HP; Ross JS
    J Gen Intern Med; 2018 Jul; 33(7):1007-1009. PubMed ID: 29687433
    [No Abstract]   [Full Text] [Related]  

  • 17. Abuses of FDA Regulatory Procedures - The Case of Suboxone.
    Haffajee RL; Frank RG
    N Engl J Med; 2020 Feb; 382(6):496-498. PubMed ID: 31914238
    [No Abstract]   [Full Text] [Related]  

  • 18. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States.
    Jones GH; Carrier MA; Silver RT; Kantarjian H
    Blood; 2016 Mar; 127(11):1398-402. PubMed ID: 26817958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Who's really raising drug prices?
    Zagorin A
    Time; 1999 Mar; 153(9):46-8. PubMed ID: 10346086
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.